99584-09-5

Basic information

• Product Name: 5-amino-3-methyl-1,3-benzoxazol-2(3H)-one(SALTDATA: FREE)
• Synonyms: 5-amino-3-methyl-1,3-benzoxazol-2(3H)-one(SALTDATA: FREE);5-amino-3-methyl-1,3-benzoxazol-2(3H)-one;MFCD09894079;5-amino-3-methylbenzo[d]oxazol-2(3H)-one
• CAS NO: 99584-09-5
• Molecular Formula: C8H8N2O2
• Molecular Weight: 164.17
• Mol File: 99584-09-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-amino-3-methyl-1,3-benzoxazol-2(3H)-one(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-3-methyl-1,3-benzoxazol-2(3H)-one(SALTDATA: FREE)(99584-09-5)
• EPA Substance Registry System: 5-amino-3-methyl-1,3-benzoxazol-2(3H)-one(SALTDATA: FREE)(99584-09-5)

Safety Data

• Hazardous Substances Data: 99584-09-5(Hazardous Substances Data)

Upstream product

• 99-57-0 2-hydroxy-5-nitroaniline 
• 3889-13-2 5-nitro-3H-benzooxazol-2-one 
• 101084-60-0 3-methyl-5-nitrobenzo[d]oxazol-2(3H)-one 

Relevant articles and documents

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS

The present invention relates to compounds of formula I wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Substituted quinazolines and analogs and use thereof

The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.